Gene therapy for wet AMD: 4-Year safety check begins
Disease control
Ongoing
This study checks the long-term safety of a gene therapy called EXG102-031 in 12 people with wet age-related macular degeneration (AMD), a condition that can cause severe vision loss. Participants already received the gene therapy in an earlier study and will be monitored for up …
Phase: PHASE1 • Sponsor: Exegenesis Bio • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC